Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $12.14 and last traded at $12.02, with a volume of 4237988 shares traded. The stock had previously closed at $10.45.
Analyst Ratings Changes
IMMX has been the topic of a number of recent research reports. Bank of America started coverage on Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective on the stock. Citizens Jmp reissued a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. HC Wainwright lifted their price objective on shares of Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Finally, Lifesci Capital began coverage on shares of Immix Biopharma in a research note on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $20.67.
View Our Latest Analysis on IMMX
Immix Biopharma Stock Up 0.8%
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities analysts anticipate that Immix Biopharma, Inc. will post -0.69 earnings per share for the current year.
Institutional Investors Weigh In On Immix Biopharma
Several institutional investors and hedge funds have recently made changes to their positions in IMMX. Allworth Financial LP acquired a new position in shares of Immix Biopharma in the 4th quarter valued at $30,000. Mathes Company Inc. purchased a new position in Immix Biopharma in the 4th quarter worth $56,000. Balyasny Asset Management L.P. acquired a new stake in Immix Biopharma during the 4th quarter worth about $67,000. Kera Capital Partners Inc. acquired a new stake in Immix Biopharma during the 4th quarter worth about $68,000. Finally, Velan Capital Investment Management LP grew its stake in Immix Biopharma by 40.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock valued at $73,000 after purchasing an additional 10,000 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.
About Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Articles
- Five stocks we like better than Immix Biopharma
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
